119 related articles for article (PubMed ID: 31011657)
1. Economic outcomes associated with an investigational drug service within a Veterans Affairs health care system.
Brown JN; Tillman F; Jacob S; Britnell SR
Contemp Clin Trials Commun; 2019 Jun; 14():100354. PubMed ID: 31011657
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Economic Value of Pharmacy Resident Participation in an Investigational Drug Service.
Brown JN; Gordon SE; Tillman F; Jacob S; Britnell SR
J Pharm Pract; 2021 Feb; 34(1):23-27. PubMed ID: 31232150
[TBL] [Abstract][Full Text] [Related]
3. Economic benefits of investigational drug services at an academic institution.
LaFleur J; Tyler LS; Sharma RR
Am J Health Syst Pharm; 2004 Jan; 61(1):27-32. PubMed ID: 14725117
[TBL] [Abstract][Full Text] [Related]
4. Costs and savings of investigational drug services.
McDonagh MS; Miller SA; Naden E
Am J Health Syst Pharm; 2000 Jan; 57(1):40-3. PubMed ID: 10630555
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a decentralized investigational drug service pharmacist in a cancer clinical trial infusion unit.
Baroody C; Sandler M; Hong C; Madanat YF; Conley S
J Oncol Pharm Pract; 2023 Oct; ():10781552231207854. PubMed ID: 37847779
[TBL] [Abstract][Full Text] [Related]
6. Development and funding of a pharmacy-based investigational drug service.
Ryan ML; Colvin CL; Tankanow RM
Am J Hosp Pharm; 1987 May; 44(5):1069-74. PubMed ID: 3605116
[TBL] [Abstract][Full Text] [Related]
7. The fall and rise of cost sharing in Kenya: the impact of phased implementation.
Collins D; Quick JD; Musau SN; Kraushaar K; Hussein IM
Health Policy Plan; 1996 Mar; 11(1):52-63. PubMed ID: 10155878
[TBL] [Abstract][Full Text] [Related]
8. Establishing a fee for handling investigational drug studies.
Ngu BQ; Schneider PJ; Kilarski DJ
Am J Hosp Pharm; 1982 Aug; 39(8):1308-10. PubMed ID: 7124750
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy-coordinated investigational drug services.
Stolar MH; Gabriel T; Grant KL; Koeller J; Letendre DE
Am J Hosp Pharm; 1982 Mar; 39(3):232-6. PubMed ID: 7072723
[TBL] [Abstract][Full Text] [Related]
10. Safety risks with investigational drugs: Pharmacy practices and perceptions in the veterans affairs health system.
Cruz JL; Brown JN
Ther Adv Drug Saf; 2015 Jun; 6(3):103-9. PubMed ID: 26240744
[TBL] [Abstract][Full Text] [Related]
11. Improving investigational drug service operations through development of an innovative computer system.
Sweet BV; Tamer HR; Siden R; McCreadie SR; McGregory ME; Benner T; Tankanow RM
Am J Health Syst Pharm; 2008 May; 65(10):969-73. PubMed ID: 18463347
[TBL] [Abstract][Full Text] [Related]
12. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Economic Impact of an Essential Service: Applying Time-Driven Activity-Based Costing to the Hospital Airway Response Team.
Stone AB; Dasani SS; Grant MC; Nascimben L; Bader AM
Anesth Analg; 2022 Mar; 134(3):445-453. PubMed ID: 35180159
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.
Perrier Q; Minoves M; Cerana S; Reymond F; Ducki C; Decaens T; Lehmann A; Bedouch P
Eur J Hosp Pharm; 2023 May; ():. PubMed ID: 37248032
[TBL] [Abstract][Full Text] [Related]
15. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Technology to Improve Efficiency in Investigational Drug Management Processes.
Mudaranthakam DP; Cernik C; Curtis L; Griffith B; Hu J; Wick J; Thompson J; Gajewski B; Koestler D; Jensen RA; Mayo MS
J Pharm Technol; 2020 Apr; 36(2):84-90. PubMed ID: 34752537
[No Abstract] [Full Text] [Related]
17. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
18. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
19. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center.
Galt KA
Pharmacotherapy; 1998; 18(5):1103-11. PubMed ID: 9758322
[TBL] [Abstract][Full Text] [Related]
20. The financial impact of investigational drug services.
Rogers SD; Lampasona V; Buchanan EC
Top Hosp Pharm Manage; 1994 Apr; 14(1):60-6. PubMed ID: 10133561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
